George D Demetri Selected Research

Dacarbazine (DIC)

12/2019	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
1/2019	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
1/2018	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
10/2017	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
1/2017	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
4/2016	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
3/2016	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George D Demetri Research Topics

Disease

101	Neoplasms (Cancer) 03/2024 - 01/2002
63	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2023 - 01/2002
43	Sarcoma (Soft Tissue Sarcoma) 05/2024 - 02/2002
21	Disease Progression 01/2021 - 10/2002
15	Liposarcoma 07/2023 - 09/2002
12	Leiomyosarcoma 12/2019 - 09/2009
11	Fatigue 01/2016 - 04/2002
7	Anemia 01/2017 - 02/2002
7	Nausea 01/2016 - 10/2006
7	Hypertension (High Blood Pressure) 08/2014 - 12/2007
7	Breast Neoplasms (Breast Cancer) 05/2008 - 03/2002
6	Thrombocytopenia (Thrombopenia) 01/2021 - 11/2002
5	Neutropenia 05/2015 - 05/2002
4	Synovial Sarcoma (Synovioma) 03/2024 - 10/2019
4	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 09/2002
4	Neoplasm Metastasis (Metastasis) 01/2018 - 07/2012
4	Cardiotoxicity 01/2016 - 05/2002
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2015 - 08/2002
4	Renal Cell Carcinoma (Grawitz Tumor) 12/2012 - 11/2006
4	Lung Neoplasms (Lung Cancer) 03/2012 - 02/2002
3	Myxoid Liposarcoma 03/2024 - 07/2007
3	Alveolar Soft Part Sarcoma 03/2016 - 12/2012
3	Vomiting 01/2016 - 06/2012
3	Genetic Translocation (Chromosomal Translocation) 07/2015 - 07/2007
3	Melanoma (Melanoma, Malignant) 09/2013 - 04/2008
3	Dermatofibrosarcoma 05/2008 - 02/2005
2	Rare Diseases (Rare Disease) 01/2022 - 09/2003
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2004
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2018 - 11/2009
2	Clear Cell Sarcoma 07/2015 - 12/2012
2	Abdominal Pain (Pain, Abdominal) 05/2015 - 03/2009
2	Weight Loss (Weight Reduction) 06/2014 - 05/2012
2	Diarrhea 06/2014 - 08/2002
2	Exanthema (Rash) 06/2014 - 07/2013
2	Stomatitis 06/2014 - 07/2013
2	Edema (Dropsy) 11/2012 - 08/2002
2	Alopecia (Baldness) 03/2012 - 05/2002
2	Leukemia 10/2009 - 11/2008
2	Aggressive Fibromatosis (Desmoid) 05/2008 - 03/2006

Drug/Important Bio-Agent (IBA)

59	Imatinib Mesylate (Gleevec)FDA Link 11/2023 - 08/2002
34	Phosphotransferases (Kinase)IBA 12/2023 - 01/2003
20	Sunitinib (Sutent)FDA Link 12/2019 - 11/2006
15	Tyrosine Kinase InhibitorsIBA 01/2021 - 08/2002
14	TrabectedinIBA 01/2021 - 01/2002
11	Proteins (Proteins, Gene)FDA Link 12/2023 - 06/2003
8	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2023 - 12/2003
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 08/2002
7	AnthracyclinesIBA 03/2024 - 02/2002
7	Dacarbazine (DIC)FDA LinkGeneric 12/2019 - 03/2016
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2024 - 02/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2009
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2021 - 09/2002
6	regorafenibIBA 01/2021 - 07/2012
5	larotrectinibIBA 12/2023 - 01/2018
5	TropomyosinIBA 12/2023 - 01/2018
5	Oncogene Proteins (Oncogene Protein)IBA 11/2012 - 01/2003
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2024 - 10/2019
4	entrectinibIBA 05/2022 - 01/2021
4	tyrosine receptor (receptor, tyrosine)IBA 01/2019 - 07/2013
4	Erythropoietin FDA Link 01/2005 - 02/2002
4	Epoetin Alfa (Epogen)FDA Link 08/2002 - 01/2002
3	Ifosfamide FDA LinkGeneric 03/2024 - 09/2009
3	Protein Isoforms (Isoforms)IBA 11/2023 - 12/2003
3	CytokinesIBA 01/2022 - 11/2002
3	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2017
3	Angiogenesis InhibitorsIBA 05/2012 - 09/2004
3	Tyrosine (L-Tyrosine)FDA Link 04/2012 - 04/2004
3	Sorafenib (BAY 43-9006)FDA Link 02/2012 - 02/2008
3	thiamine triphosphorate (TTP)IBA 07/2010 - 11/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2008 - 03/2002
3	Hemoglobins (Hemoglobin)IBA 01/2005 - 08/2002
2	HLA-A Antigens (HLA-A)IBA 03/2024 - 10/2019
2	ChromatinIBA 07/2023 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 03/2020
2	Gemcitabine FDA Link 01/2021 - 05/2007
2	Therapeutic UsesIBA 01/2020 - 06/2003
2	pazopanib FDA Link 08/2019 - 05/2012
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2012
2	eribulin FDA Link 10/2017 - 04/2016
2	Microphthalmia-Associated Transcription FactorIBA 07/2015 - 12/2012
2	nilotinib FDA Link 05/2015 - 09/2009
2	Tumor Biomarkers (Tumor Markers)IBA 09/2014 - 06/2003
2	Small Interfering RNA (siRNA)IBA 09/2014 - 07/2013
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2013 - 09/2006
2	TOR Serine-Threonine KinasesIBA 07/2013 - 01/2012
2	ridaforolimusIBA 07/2013 - 01/2012
2	Transaminases (Aminotransferases)IBA 06/2012 - 05/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2008 - 03/2003
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2008 - 11/2002
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2007 - 06/2005
2	Semaxinib (SU5416)IBA 01/2005 - 09/2004
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2005 - 09/2004
2	Troglitazone (Rezulin)FDA Link 06/2003 - 09/2002

Therapy/Procedure

72	Therapeutics 03/2024 - 01/2002
28	Drug Therapy (Chemotherapy) 05/2024 - 01/2002
4	Intravenous Infusions 05/2015 - 10/2002
3	Immunotherapy 11/2019 - 01/2017
2	Aftercare (After-Treatment) 07/2012 - 05/2006
2	Radiotherapy 04/2012 - 01/2008
2	Adjuvant Chemotherapy 05/2008 - 03/2003